Mink Therapeutics Stock Net Income
| INKT Stock | USD 0.93 0.06 6.90% |
Mink Therapeutics fundamentals help investors to digest information that contributes to Mink Therapeutics' financial success or failures. It also enables traders to predict the movement of Mink Stock. The fundamental analysis module provides a way to measure Mink Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mink Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -24.8 M | -26 M | |
| Net Loss | -25.2 M | -26.5 M | |
| Net Loss | -22.5 M | -23.6 M | |
| Net Loss | (0.65) | (0.69) | |
| Net Income Per E B T | 0.89 | 1.02 |
Mink | Net Income |
Mink Therapeutics Company Net Income Analysis
Mink Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Mink Therapeutics Net Income | (22.46 M) |
Most of Mink Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mink Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Mink Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Mink Therapeutics is extremely important. It helps to project a fair market value of Mink Stock properly, considering its historical fundamentals such as Net Income. Since Mink Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Mink Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Mink Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Mink Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Mink Therapeutics reported net income of (22.46 Million). This is 106.58% lower than that of the Biotechnology sector and 132.06% lower than that of the Health Care industry. The net income for all United States stocks is 103.93% higher than that of the company.
Mink Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mink Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mink Therapeutics could also be used in its relative valuation, which is a method of valuing Mink Therapeutics by comparing valuation metrics of similar companies.Mink Therapeutics is currently under evaluation in net income category among related companies.
Mink Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Mink Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Mink Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Mink Therapeutics' value.| Shares | Jane Street Group, Llc | 2023-12-31 | 18.4 K | Wells Fargo & Co | 2023-12-31 | 11.5 K | Northern Trust Corp | 2023-12-31 | 11.1 K | Tower Research Capital Llc | 2023-12-31 | 10.9 K | Virtu Financial Llc | 2023-12-31 | 10.6 K | Ubs Group Ag | 2023-12-31 | 5 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 4.5 K | Qube Research & Technologies | 2023-12-31 | 1.9 K | Artal Group S A | 2023-12-31 | 1.9 K | Vanguard Group Inc | 2023-12-31 | 234.2 K | Longbow Finance Sa | 2023-12-31 | 166.7 K |
Mink Fundamentals
| Return On Equity | -12.39 | ||||
| Return On Asset | -1.1 | ||||
| Current Valuation | 28.82 M | ||||
| Shares Outstanding | 34.7 M | ||||
| Shares Owned By Insiders | 71.30 % | ||||
| Shares Owned By Institutions | 2.98 % | ||||
| Number Of Shares Shorted | 48.46 K | ||||
| Price To Book | 10.05 X | ||||
| EBITDA | (22.72 M) | ||||
| Net Income | (22.46 M) | ||||
| Cash And Equivalents | 29.85 M | ||||
| Cash Per Share | 0.88 X | ||||
| Total Debt | 65.42 M | ||||
| Current Ratio | 1.74 X | ||||
| Book Value Per Share | (0.52) X | ||||
| Cash Flow From Operations | (15.76 M) | ||||
| Short Ratio | 0.26 X | ||||
| Earnings Per Share | (0.65) X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 31 | ||||
| Beta | 0.12 | ||||
| Market Capitalization | 32.18 M | ||||
| Total Asset | 4.55 M | ||||
| Retained Earnings | (133.4 M) | ||||
| Working Capital | (7.8 M) | ||||
| Net Asset | 4.55 M |
About Mink Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mink Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mink Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mink Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Mink Therapeutics Piotroski F Score and Mink Therapeutics Altman Z Score analysis. For more information on how to buy Mink Stock please use our How to Invest in Mink Therapeutics guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Mink Stock analysis
When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Mink Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mink Therapeutics. If investors know Mink will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mink Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Return On Assets (1.10) | Return On Equity (12.39) |
The market value of Mink Therapeutics is measured differently than its book value, which is the value of Mink that is recorded on the company's balance sheet. Investors also form their own opinion of Mink Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mink Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mink Therapeutics' market value can be influenced by many factors that don't directly affect Mink Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mink Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mink Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mink Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.